Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
49 hedge funds and large institutions have $13.7M invested in Harpoon Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 15 closing their positions.
314% more call options, than puts
Call options by funds: $29K | Put options by funds: $7K
6% less funds holding
Funds holding: 52 → 49 (-3)
8.7% less ownership
Funds ownership: 65.5% → 56.8% (-8.7%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
35% less capital invested
Capital invested by funds: $21M → $13.7M (-$7.34M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$468K |
| 2 |
LCS
Levin Capital Strategies
New York
|
+$278K |
| 3 |
TI
Telemetry Investments
New York
|
+$78.3K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$59.2K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$50.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.27M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$769K |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$563K |
| 4 |
BlackRock
New York
|
-$281K |
| 5 |
Renaissance Technologies
New York
|
-$125K |
HARP Hedge Fund Activity: Q4 2022 in Review
49 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q4 2022, worth a combined $13.7M — down 35% from $21M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of HARP and 13 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $468K. The largest seller was OrbiMed, cutting an estimated $1.27M.
- 49 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q4 2022, down from 52 in Q3 2022.
- Funds reported $13.7M of Harpoon Therapeutics, Inc. Common Stock stock for Q4 2022, down 35% quarter-over-quarter.
- 13 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q4 2022 and 15 closed out, a net change of -2 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $468K added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q4 2022 was OrbiMed, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2022.